CN102869328A - 一种用于获取和处理源自生理组织的材料的全套设备 - Google Patents
一种用于获取和处理源自生理组织的材料的全套设备 Download PDFInfo
- Publication number
- CN102869328A CN102869328A CN2010800666008A CN201080066600A CN102869328A CN 102869328 A CN102869328 A CN 102869328A CN 2010800666008 A CN2010800666008 A CN 2010800666008A CN 201080066600 A CN201080066600 A CN 201080066600A CN 102869328 A CN102869328 A CN 102869328A
- Authority
- CN
- China
- Prior art keywords
- complete set
- tissue
- equipment
- rotor
- centrifuge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 17
- 238000012545 processing Methods 0.000 title abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000001519 tissue Anatomy 0.000 claims description 23
- 230000007246 mechanism Effects 0.000 claims description 22
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 15
- 108010073385 Fibrin Proteins 0.000 claims description 13
- 102000009123 Fibrin Human genes 0.000 claims description 13
- 229950003499 fibrin Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 239000010408 film Substances 0.000 claims description 6
- 230000008520 organization Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000010409 thin film Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000000560 biocompatible material Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000000249 desinfective effect Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 3
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- 102000013275 Somatomedins Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000282 fibrinogen degradation product Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000002992 dental papilla Anatomy 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/10—Apparatus for enzymology or microbiology rotatably mounted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3616—Blood, e.g. platelet-rich plasma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/12—Apparatus for enzymology or microbiology with sterilisation, filtration or dialysis means
- C12M1/121—Apparatus for enzymology or microbiology with sterilisation, filtration or dialysis means with sterilisation means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/05—Means for pre-treatment of biological substances by centrifugation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- External Artificial Organs (AREA)
Abstract
一种可获取和处理源自生理组织、尤其是人体血液的材料的全套设备，包括分离机构，用于移除生理组织的一部分；混合机构，用于处理之前移除的部分；注射机构，用于注射凝块；成膜机构，用于使凝块成为一层薄膜；以及定位机构，用于定位形成的薄膜。
Description
技术领域
本发明涉及生理组织的修复、治疗和处理，尤其涉及一种修复和处理生理组织的全套设备以及修复、治疗和处理生理组织的方法。
背景技术
寻找促进止血和伤口愈合的方法是所有外科领域面临的一个问题。外科医生的梦想是能有一种神奇胶水，可修复伤口，而不会造成坏死，同时能避免每次外科手术的所有后遗症（感染、血肿、撕伤等）。一般血液是可从每类病人均能方便获得的组织。目前已知很多有利于生成外科处理材料的各类组织，其中包括：纤维蛋白胶（Tissucol Baxter）、血小板浓缩液cPRP（Marx 1998）、高浓度血小板血浆（PRP）、富含生长因子血浆（PRGFs，E.Anitua）、富含血纤蛋白血浆（2001J.Choukroun）。
发明内容
本发明设计出了一种基于使用生长因子获得材料的方法。
生长因子会自然产生，因此可从组织或细胞中提取并进行处理：脑下垂体激素、血小板源性生长因子（PDGFs）、降钙素、胰岛素样生长因子（IGFs）、成纤维细胞生长因子（FGFs）、细胞因子类，尤其是IL-1和TNF-α、骨原壳蛋白（OPG）、胰岛素样生长因子（IGF-I和IGF-II）等；另外它们可以人工合成，可采用下述材料合成：生长因子、碱性磷酸酶、骨形态发生蛋白等。本发明提供了一种从生理组织中分离出的材料，可直接用于重建组织且易于获得。该材料在下文中称作C.G.F.（浓缩生长因子，concentrated growthfactor）。
C.G.F.是一种愈合伤口的生物材料，与血小板浓缩液相比具有独特性质和特点。该材料的制备过程、生物化学特性、结构、凝块组成、血纤蛋白结构、血小板细胞因子的作用、白细胞活化、C.G.F.与骨细胞之间的潜在相互作用、与软组织的潜在应用和骨再生等方面，均使其是一种易于生产，并可在多种临床应用中使用，获得令人意想不到的效果的生物材料。
C.G.F既可促进组织的伤口愈合，这源于其有效的新生血管的生长，同时也有利于有关疤痕组织的快速再建模的外科伤口愈合，而几乎不会造成感染后遗症。
与所有其它血小板浓缩液，特别是PRP相比，其提取技术除了需血液外，无需添加任何其它成分（如为PRP，则需添加凝血酶和氯化钙）。
其在牙周病学方面的应用，有利于稳定边缘牙周组织以及获得最佳修补审美效果。可通过促进齿颈对齐以及添加牙乳头来维护或重建最初的骨体积，改进了修复体暴露出部分的外形。
C.G.F.的使用便于外科手术部位的操作管理，加强移植性生物材料的吸收和重建模。C.G.F.由血浆细胞因子类含量较高的自体纤维蛋白基质和并入此材料内的白细胞源性细胞因子类构成。可以说，这种免疫血小板浓缩液具有以下四个关键特征：
纤维蛋白凝块由于其刚性而起着非常重要的机械作用，其颗粒物与移植材料混合时会形成生物交联剂。
-移植材料部分用C.G.F.颗粒物补充时，会促进细胞迁移，尤其是内皮细胞迁移，形成新生血管，这对移植组织上血管的形成和存活非常关键。
-血浆细胞因子类可在纤维蛋白基质的重吸收的基础上使伤口稳定愈合。
-最后，由于凝块中存在白细胞，所以对添加炎性和抗炎细胞因子类来说免疫功能尤为重要。这些分子的渐进规则对移植部位的抗炎和感染症状起着自我调节的作用。
研究表明单独的纤维蛋白就可使血管再生。这一极其重要的特性可通过纤维蛋白凝胶的三维结构和捕集在网状结构中的细胞因子类的联合作用进行说明。
纤维蛋白和纤维蛋白原降解产物可促进中性粒细胞的迁移，增加在其表面的CD11/CD18受体的能力，其受体不仅可使中性粒细胞粘附于内皮和跨移，而且使其同时粘附于纤维蛋白原上。进一步地，这些成分还可调节吞噬作用和酶降解过程。
纤维蛋白基质通过在上皮细胞和成纤维细胞上作用使受损部位覆盖愈合。所有这些因素使我们可将C.G.F.作为一种纤维蛋白凝块，它能增进微血管形成，且能促进上皮细胞向其表面迁移。
本发明的目的在于提供一种用于获取和处理源自生理组织、尤其是人体血液的材料的全套设备，包括分离机构，用于移除生理组织的一部分；混合机构，用于处理之前移除的部分；注射机构，用于注射凝块；成膜机构，用于使凝块成为一层薄膜；以及定位机构，用于定位形成的薄膜。
所述分离机构包括离心机，用于从血液中分离纤维蛋白和凝块，所述离心机可以按指定速度运行，其上安装了相匹配的转子；进一步地，所述离心机上还安装了用于给处理过的组织消毒的机构。优选地，所述消毒机构包括紫外线灯。
用于处理移除部分的混合机构包括旋转式混合机，所述混合机可将生理组织与包括其它生物组织如骨组织或其它生物相容材料等的可选填料混合。
以下将通过实施例并结合附图详细说明本发明设备的其它优点和特点，但对该实施例的描述仅限于说明目的，并不对本发明造成限制。
附图说明
图1A为本发明所述全套设备的第一部件的部分结构被拆开的立面图；
图1B为图1A中部件的侧视图；
图2为本发明所述全套设备的第二部件各截面部分的平面图；
图3为本发明所述全套设备的第三部件的平面图；
图4为图3中所示结构的部分分解放大详图；
图5为图4所述的部分的侧视详图；以及
图6和图7是本发明所述全套设备的第四部件的两个视图。
具体实施方式
图1A展示了本发明所述全套设备的第一部件，编号1代表离心机的主体，其中离心机上设置了盖住箱体201的盖子101，转子301设置在箱体内，转子上设置了用于放置试管401的多个卡座311。图1B中，离心机1内部设置了一个朝向箱体201的杀菌灯501。该离心机是用于处理刚抽取的血液，具有如下特征：首先，一体式转子301与试管成一定的倾斜角，优选是相对于转子的转轴成30°~50°的倾斜角。紫外线杀菌灯501设置在箱体201内，以优化针对败血症方面的处理操作安全性。
加速和减速可被控制，以避免在离心机作用下分离材料时出现问题。转子的冷却可被控制，以获得提高的性能水平。试管卡座可方便地通过高压蒸气灭菌器进行灭菌处理。最后，在一个循环结束后离心机可使盖子自动打开。
图2展示了本发明成套设备的第二部件，其中编号2代表纤维蛋白注射器。该注射器包括一个第一圆柱体102，圆柱体上匹配设置有一个可滑移的活塞，活塞在圆柱体102内形成的腔室112内滑移。圆柱体102上设置了圈环142形式的抓取机构，同样的，圈环222作为活塞202的抓取机构。活塞内设置了匹配的软杆212，软杆212沿着腔室112的限位器122和轴向腔体132内的导管302设置，与限位器122连通。导管的另一端设置在第二圆柱体402的端部412处，活塞202通过与其连接的软杆212在第二圆柱体402的腔室422内滑移而被驱动。
第二圆柱体402的端部442与轴向腔体612匹配连接，与第三圆柱体602的腔室642连通。密封机构632的活塞622在第三圆柱体602内滑移。该圆柱体具有一个径向凸缘652，向外突出，可用作把手。
图3展示了本发明全套设备的第三部件，编号3代表了成膜机构，该成膜机构根据本发明通过对生物组织进行处理生成薄膜。该成膜机构3是一个带两个臂部103的钳子，臂部一端设置了多个抓取环113，臂部在轴203处轴转动作，另一端设置了延伸部303，两个圆盘403分别与其相连。
图4为图3的部分结构截面详图，参考编号说明参见相同部分。图中示出了各圆盘403如何通过钻孔的板313固定在延伸部303上的，其中适用的螺钉323旋入从圆盘403突出的轴向舌柄413中心形成的螺纹孔423。图5进一步说明了延伸部303、板313和连接机构323的位置。
图6和图7为本发明全套设备的第四部件。编号4代表涂抹工具，包括一个涂抹针104，其端部连接了两个分别带一个桨状元件124的刷子114；如图7所示，两个桨片124互相成180°设置。每个桨片均呈曲状。
通过下述内容可清楚了解本发明全套设备的运行原理。从病人的身上提取整个血液组织，用于该病人疤痕重建治疗。用本发明全套设备内专用的离心机处理血液，三个部分被分离出：血浆、纤维蛋白成分和含血小板的红细胞成分。然后将纤维蛋白浓缩液与凝块和可选填料在旋转式混合机中混合，然后进行进一步的处理步骤。最终获得的组织的特点是可形成具有很大构型潜能的弹性多分子网状结构；因此可制成非常易于应用于待治疗部位的膜状结构。
同样，获得的材料可通过注射器机构以挤压方式进行注射。该材料会进入注射器的第三圆柱体，即具有较大截面积的那个圆柱体，然后装入可将其置入设备部分输入腔体，用于治疗。
Claims (7)
1.一种用于获取和处理源自生理组织、尤其是人体血液的材料的全套设备，包括分离机构，用于移除生理组织的一部分；混合机构，用于处理所述之前移除的部分；注射机构，用于注射凝块；成膜机构，用于使凝块成为一层薄膜；以及定位机构，用于定位形成的薄膜。
2.根据权利要求1所述的全套设备，其中该分离结构包括离心机，用于从血液中分离纤维蛋白和凝块，所述离心机可以按指定速度运行，其上安装了相匹配的转子，设于相配的箱体内。
3.根据权利要求2所述的全套设备，其中该转子的试管卡座相对于转子转轴的倾斜角为30°~50°。
4.根据权利要求3所述的全套设备，其中该转子的试管卡座倾斜角为32°。
5.根据权利要求1至4中任一项权利要求所述的全套设备，其中所述离心机上安装了用于给内置转子的箱体消毒的机构。
6.根据权利要求5所述的全套设备，其中消毒机构包括一个紫外线灯。
7.根据权利要求1至6任一项权利要求所述的设备，其中用于处理移除部分的混合机构包括旋转式混合机，所述混合机将生理组织与包括其它生物组织如骨组织或其它生物相容材料等的可选填料混合。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2010/000200 WO2011138803A1 (en) | 2010-05-06 | 2010-05-06 | Kit for obtaining and processing a material derived from a physiological tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102869328A true CN102869328A (zh) | 2013-01-09 |
Family
ID=44140797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800666008A Pending CN102869328A (zh) | 2010-05-06 | 2010-05-06 | 一种用于获取和处理源自生理组织的材料的全套设备 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2566426A1 (zh) |
| KR (1) | KR20130107197A (zh) |
| CN (1) | CN102869328A (zh) |
| WO (1) | WO2011138803A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106890732A (zh) * | 2017-04-07 | 2017-06-27 | 长沙湘智离心机仪器有限公司 | 一种美容离心机及其操作方法 |
| CN112888773A (zh) * | 2018-10-11 | 2021-06-01 | 帝斯曼知识产权资产管理有限公司 | 生物组织处理设备 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11191698B2 (en) * | 2017-11-03 | 2021-12-07 | Enso Discoveries, Llc | Apparatus and method for processing platelet rich fibrin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0392218A2 (en) * | 1989-04-17 | 1990-10-17 | Dorin Olimpiu Petrescu | Process for the in vitro preparation of artificial haemostatic membranes |
| US20050186193A1 (en) * | 2002-04-13 | 2005-08-25 | Allan Mishra | Method and kit for treatment of tissue injury |
| WO2007005820A1 (en) * | 2005-06-30 | 2007-01-11 | Cytomedix, Inc. | Method for treating wounds with enriched platelet wound healant |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022501A1 (it) * | 2002-11-26 | 2004-05-27 | Dorin Olimpiu Petrescu | Medicazione organica cicatrizzante ed emostatica. |
-
2010
- 2010-05-06 KR KR1020127030633A patent/KR20130107197A/ko not_active Application Discontinuation
- 2010-05-06 WO PCT/IT2010/000200 patent/WO2011138803A1/en active Application Filing
- 2010-05-06 CN CN2010800666008A patent/CN102869328A/zh active Pending
- 2010-05-06 EP EP10736804A patent/EP2566426A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0392218A2 (en) * | 1989-04-17 | 1990-10-17 | Dorin Olimpiu Petrescu | Process for the in vitro preparation of artificial haemostatic membranes |
| US20050186193A1 (en) * | 2002-04-13 | 2005-08-25 | Allan Mishra | Method and kit for treatment of tissue injury |
| WO2007005820A1 (en) * | 2005-06-30 | 2007-01-11 | Cytomedix, Inc. | Method for treating wounds with enriched platelet wound healant |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106890732A (zh) * | 2017-04-07 | 2017-06-27 | 长沙湘智离心机仪器有限公司 | 一种美容离心机及其操作方法 |
| CN112888773A (zh) * | 2018-10-11 | 2021-06-01 | 帝斯曼知识产权资产管理有限公司 | 生物组织处理设备 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011138803A1 (en) | 2011-11-10 |
| EP2566426A1 (en) | 2013-03-13 |
| KR20130107197A (ko) | 2013-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choukroun et al. | Platelet rich fibrin in regenerative dentistry | |
| US20210346587A1 (en) | New standardizations & medical devices for the preparation of platelet rich plasma (prp) or bone marrow concentrate (bmc) alone or in combination with hyaluronic acid | |
| Bielecki et al. | Platelet-rich plasma (PRP) and Platelet-Rich Fibrin (PRF): surgical adjuvants, preparations for in situ regenerative medicine and tools for tissue engineering | |
| Chou et al. | Autologous platelet concentrates in maxillofacial regenerative therapy | |
| JP4173205B2 (ja) | 自家移植用血漿とフィブリンゲルの調合 | |
| US20150190969A1 (en) | Bone regeneration material | |
| JP2004500026A (ja) | 自己由来トロンビン | |
| CN115624569A (zh) | 伤口修复剂组合物的制备工艺、管子及装置 | |
| WO2013061309A2 (en) | New a-prp medical device & tissue engineering composition, manufacturing machines and process | |
| CA2767674A1 (en) | A process comprising application of sub-atmospheric pressure for obtaining growth factors from platelets | |
| CN102869328A (zh) | 一种用于获取和处理源自生理组织的材料的全套设备 | |
| Giannini et al. | Use of autologous fibrin-platelet glue and bone fragments in maxillofacial surgery | |
| Khanzadeh Alishahi et al. | Histopathological evaluation of the effect of platelet-rich fibrin on canine cutaneous incisional wound healing | |
| Quirynen et al. | Leukocyte-and Platelet-Rich Fibrin in Oral Regenerative Procedures: Evidence-Based Clinical Guidelines | |
| TWI736824B (zh) | 分離血液的方法 | |
| Azzaldeen et al. | Platelet-rich fibrin (PRF) in dentistry | |
| Yaltirik et al. | Platelet-rich plasma in trauma patients | |
| Bhangdiya et al. | An overview on platelet concentrates in tissue regeneration in periodontology. | |
| Chowdhury et al. | Use of Chouk-roun's Platelet Rich Fibrin in Oral Defects | |
| Mani et al. | PRF-AN ASSET TO PERIODONTAL REGENERATION. | |
| Shevchenko et al. | Technologies for producing platelet masses for regenerative medicine | |
| Singh et al. | Application of PRF and PRP in Periodontics and Implantology: A Review | |
| Imran et al. | Platelet Rich Fibrin–Evolution and Application in Oral and Maxillofacial Surgery | |
| Chhabra et al. | Platelet Rich Fibrin-Evolution, Preparation and its Clinical Implications | |
| Pedro | The effect of platelet rich fibrin in oral surgery: a literature review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130109 |